Calquence Connections


Understanding Chronic Lymphocytic Leukemia (CLL)

A Patient’s View on Navigating the Healthcare System

Find a Treatment for CLL

Expectations and Outcomes from Treatment

Communication with your Care Team


More Information on CALQUENCE


CALQUENCE is a prescription medicine used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

It is not known if CALQUENCE is safe and effective in children.

Important Safety Information About CALQUENCE® (acalabrutinib) capsules

Before taking CALQUENCE, tell your healthcare provider about all of your medical conditions, including if you:

  • have had recent surgery or plan to have surgery. Your healthcare provider may stop CALQUENCE for any planned medical, surgical, or dental procedure.
  • have bleeding problems.
  • have or had heart rhythm problems.
  • have an infection.
  • have or had liver problems, including hepatitis B virus (HBV) infection.
  • are pregnant or plan to become pregnant. CALQUENCE may harm your unborn baby and cause problems during childbirth (dystocia).
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with CALQUENCE
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with CALQUENCE and for at least 1 week after the last dose of CALQUENCE
  • are breastfeeding or plan to breastfeed. It is not known if CALQUENCE passes into your breast milk. Do not breastfeed during treatment with CALQUENCE and for at least 2 weeks after your final dose of CALQUENCE.

Tell your healthcare provider about all the medicines you take, including prescription and over-the­-counter medicines, vitamins, and herbal supplements. Taking CALQUENCE with certain other medications may affect how CALQUENCE works and can cause side effects. Especially tell your healthcare provider if you take a blood thinner medicine.

How should I take CALQUENCE?
  • Take CALQUENCE exactly as your healthcare provider tells you to take it.
  • Do not change your dose or stop taking CALQUENCE unless your healthcare provider tells you to.
  • Your healthcare provider may tell you to decrease your dose, temporarily stop, or completely stop taking CALQUENCE if you develop certain side effects.
  • Take CALQUENCE 2 times a day (about 12 hours apart).
  • Take CALQUENCE with or without food.
  • Swallow CALQUENCE capsules whole with a glass of water. Do not open, break, or chew capsules.
  • If you need to take an antacid medicine, take it either 2 hours before or 2 hours after you take CALQUENCE.
  • If you need to take certain other medicines called acid reducers (H2-receptor blockers), take CALQUENCE 2 hours before the acid reducer medicine.
  • If you miss a dose of CALQUENCE, take it as soon as you remember. If it is more than 3 hours past your usual dosing time, skip the missed dose and take your next dose of CALQUENCE at your regularly scheduled time. Do not take an extra dose to make up for a missed dose.
What are the possible side effects of CALQUENCE?
CALQUENCE may cause serious side effects, including:
  • Serious infections can happen during treatment with CALQUENCE and may lead to death. Your healthcare provider may prescribe certain medicines if you have an increased risk of getting infections. Tell your healthcare provider right away if you have any signs or symptoms of an infection, including fever, chills, or flu-like symptoms.
  • Bleeding problems (hemorrhage) can happen during treatment with CALQUENCE and can be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs or symptoms of bleeding, including blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding or bleeding that is severe or you cannot control, vomit blood or vomit that looks like coffee grounds, cough up blood or blood clots, dizziness, weakness, confusion, changes in your speech, headache that lasts a long time, or bruising or red or purple skin marks
  • Decrease in blood cell counts. Decreased blood counts (white blood cells, platelets, and red blood cells) are common with CALQUENCE, but can also be severe. Your healthcare provider should do blood tests to check your blood counts regularly during treatment with CALQUENCE.
  • Second primary cancers. New cancers have happened in people during treatment with CALQUENCE, including cancers of the skin or other organs. Your healthcare provider will check you for skin cancers during treatment with CALQUENCE. Use sun protection when you are outside in sunlight.
  • Heart rhythm problems (atrial fibrillation and atrial flutter) have happened in people treated with CALQUENCE. Tell your healthcare provider if you have any of the following signs or symptoms: fast or irregular heartbeat, dizziness, feeling faint, chest discomfort, or shortness of breath

The most common side effects of CALQUENCE include headache, diarrhea, muscle and joint pain, upper respiratory tract infection, and bruising.

These are not all the possible side effects of CALQUENCE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information.

Please see full Prescribing Information, including Patient Information.

Meet the Speakers


Marsena Pelton, MSN, RN, OCN: Hello, my name is Marsena Pelton and I’m an oncology nurse educator with AstraZeneca. I’d like to welcome you to CALQUENCE Connections.

Today’s program, which is being brought to you by AstraZeneca and CURE® magazine, will feature information about chronic lymphocytic leukemia, or CLL, as well as CALQUENCE® (acalabrutinib), a targeted treatment option.

To start off, I’d like to share some information with you, then we’ll have a conversation with a CLL patient and his care team. After that, we’ll have some time for Q and A, taking questions you shared during registration for this event and also those submitted during the program.

Sound good? Let’s get started.

CALQUENCE, or acalabrutinib, is a targeted treatment option that is indicated to treat adults with CLL or SLL (small lymphocytic lymphoma), offering an alternative to traditional chemotherapy.

CALQUENCE is a kinase inhibitor that affects the growth of cancerous B cells. Kinases play a role in activating chemical pathways within cells, some of which can start or maintain the growth of new cells. This medicine works by blocking a protein called Bruton tyrosine kinase, or BTK, in B cells.

CALQUENCE is a prescription oral treatment for adults with CLL or SLL.

CALQUENCE may cause serious side effects including:

  • serious infections,
  • bleeding problems,
  • decrease in blood cell count,
  • new cancers,
  • and heart rhythm problems.

Some may lead to death.

Tell your doctor if you experience infections such as flu-like symptoms; unexpected bleeding such as blood in your stool or urine; or heart rhythm problems such as fast or irregular heartbeat. Use sun protection when outside.

With that in mind, let’s shift over to our panel and learn about some real‐life experiences with managing CLL and treatment with CALQUENCE.

At this time, I’d like to introduce:

  • Jim, who is a patient with CLL.
  • Becky, who is Jim's wife and caregiver.
  • Dr Jeff Sharman, a medical oncologist from Willamette Valley Cancer Institute and Research Center, and
  • Nichole Fisher, BSN, RN, an oncology nurse, also from Willamette Valley Cancer Institute and Research Center

CALQUENCE is a registered trademark of the AstraZeneca group of companies.

©2021 AstraZeneca. All rights reserved. US-49150 Last Updated 5/21